Evidence map›Paper›PMID 36291575›Full record

ArticleBiomolecules2022

Prostate Cancer-Associated miRNAs in Saliva: First Steps to an Easily Accessible and Reliable Screening Tool.

Christoph Luedemann, Jan-Ludwig Reinersmann, Claudia Klinger, Stephan Degener, Nici Markus Dreger, Stephan Roth, Michael Kaufmann, Andreas Savelsbergh

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 3 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Salivary Extracellular Vesicles: Biomarkers and Beyond in Human Diseases.International journal of molecular sciences · 2023
    Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Obtaining miRNA from Saliva-Comparison of Sampling and Purification Methods.International journal of molecular sciences · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Christoph LuedemannDepartment of Internal Medicine, Gastroenterology, Hepatology, Infectiology, Nephrology, Endocrinology & Diabetology, University Hospital of Bonn, 53127 Bonn, Germany.
Jan-Ludwig ReinersmannDivision of Functional Genomics, Chair for Biochemistry and Molecular Medicine, University of Witten/Herdecke, 58453 Witten, Germany.
Claudia KlingerDivision of Functional Genomics, Chair for Biochemistry and Molecular Medicine, University of Witten/Herdecke, 58453 Witten, Germany.
Stephan DegenerDepartment of Urology, Helios University Hospital Wuppertal, University of Witten/Herdecke, 42283 Wuppertal, Germany.
Nici Markus DregerDepartment of Urology, Helios University Hospital Wuppertal, University of Witten/Herdecke, 42283 Wuppertal, Germany.
Stephan RothDepartment of Urology, Helios University Hospital Wuppertal, University of Witten/Herdecke, 42283 Wuppertal, Germany.
Michael KaufmannDivision of Functional Genomics, Chair for Biochemistry and Molecular Medicine, University of Witten/Herdecke, 58453 Witten, Germany.
Andreas SavelsberghDivision of Functional Genomics, Chair for Biochemistry and Molecular Medicine, University of Witten/Herdecke, 58453 Witten, Germany.ORCID 0000-0002-6136-3230
Witten/Herdecke University · DEHelios Universitätsklinikum Wuppertal · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCommon diagnostic tools for prostate cancer-prostate-specific antigen and transrectal biopsy-show only low predictive value and poor sensitivity. This study examines circulating miRNA in saliva to explore the possibility of a non-invasive and easy-to-execute diagnostic tool for prostate cancer screenings.

methods16 miRNAs were extracted from salivary exosomes and analyzed via the delta-CT method. The presented method enables an application of the test in any health institution and even outpatient sector. Recruited participants were suspected to suffer from prostate cancer due to elevated PSA serum levels. Of these participants, 43 were diagnosed with prostate cancer, while 31 suffered from benign diseases and served as control group.

resultshsa-mir-331-3p and hsa-mir-200b were significantly reduced in prostate cancer patients compared to the control group. ROC curve analysis revealed a reliable differentiation strength (AUC > 0.6) for both miRNAs with positive predictive values of 71% indicating prostate cancer. Differentiation of both groups based on PSA serum measurements was insufficient. The other 14 examined miRNAs showed no significant group differences.

conclusionsThe presented method and miRNA are promising non-invasive tools to augment the current prostate cancer screening, thereby improving screening sensitivity and reducing numbers of false positive cancer suspects admitted to further invasive diagnostic and therapeutic steps.

Indexed as

MicroRNAsProstatic NeoplasmsBiomarkers, TumorEarly Detection of CancerHumansMaleProstate-Specific AntigenSalivaBiomarkers, TumorMicroRNAsProstate-Specific Antigenbiomarkerscirculating miRNAhsa-mir-200bhsa-mir-331-3pmiRNAprostate cancersalivary exosomes

Identifiers

PMID36291575
PMCPMC9599776
OpenAlexW4297147387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.